Lemonade
LMND
$70.62
+0.16%
Lemonade, Inc. operates a digital and AI-powered platform for property and casualty insurance, offering renters, homeowners, pet, and life insurance policies in the U.S. and Europe. As a disruptor in the traditional insurance industry, Lemonade leverages artificial intelligence, behavioral economics, and a transparent, socially-conscious business model to differentiate itself from legacy carriers. The current investor narrative centers on the company's accelerating revenue growth and improving loss ratio, which signal a path toward profitability, though concerns persist about its expensive valuation and continued net losses. Recent news highlights a Morgan Stanley downgrade on valuation after a sharp rally, while the company's autonomous vehicle insurance partnership with Tesla has generated excitement around its AI-first approach.…
LMND
Lemonade
$70.62
Related headlines
Investment Opinion: Should I buy LMND Today?
Rating: Hold. Lemonade is a high-growth, unprofitable disruptor with accelerating revenue and improving margins, but its premium valuation and limited analyst coverage warrant caution. The consensus from 2 analysts implies a forward PS of 1.96, but the lack of a clear average target makes it difficult to assess upside. Supporting Evidence: Revenue growth accelerated to 53.3% YoY in Q4 2025, gross margin improved to 63.0% from 26.3% in Q1 2025, and free cash flow turned positive at $17.6M. However, the trailing PS of 6.93 is 362% above the industry average of 1.5, and the company still posts negative EPS of -$0.33. The forward PS of 1.96 is closer to fair value but assumes continued rapid growth. Risks & Conditions: The biggest risks are growth deceleration below 30% YoY, a reversal in margin improvement, or a broad market rotation away from growth stocks. This Hold would upgrade to Buy if the forward PS compresses below 1.5x (in line with industry) or if the company achieves positive net income. It would downgrade to Sell if revenue growth falls below 20% or if the stock breaks below $50 support. Overall, LMND is overvalued on a trailing basis but fairly valued on forward metrics, making it a hold for existing investors and a cautious buy for those with a high risk tolerance.
Sign up to view all
LMND 12-Month Price Forecast
Lemonade's accelerating growth and improving margins are impressive, but the stock's premium valuation leaves little room for error. The base case of 35-40% growth and continued margin improvement is most likely, with the stock trading in a range. The bull case requires positive net income and analyst upgrades, while the bear case hinges on growth deceleration or adverse claims. Given the limited analyst coverage and high volatility, a neutral stance with medium confidence is appropriate. An upgrade to bullish would require sustained 50%+ growth and positive net income, while a downgrade to bearish would follow two consecutive quarters of growth below 30%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Lemonade's 12-month outlook, with a consensus price target around $91.81 and implied upside of +30.0% versus the current price.
Average Target
$91.81
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$57 - $92
Analyst target range
Only 2 analysts cover Lemonade, which is limited for a company of its market cap ($5.1 billion). The consensus recommendation is not explicitly provided, but the average EPS estimate of $2.72 for the next fiscal year implies a forward PE of approximately 25.9x, which would be a significant improvement from current losses. The average revenue estimate is $2.607 billion, implying a forward PS of 1.96. With only 2 analysts, the consensus leans cautiously optimistic, but coverage is too thin to draw strong conclusions. The estimated EPS range is $2.67 to $2.79, and the revenue range is $2.569 billion to $2.651 billion, indicating relatively tight dispersion. The high estimate assumes continued rapid growth and margin expansion, while the low estimate likely prices in slower growth or higher claims. The limited analyst coverage means the stock may experience higher volatility and less efficient price discovery, as institutional interest is lower. Investors should supplement analyst views with their own fundamental analysis and monitor for upgrades or downgrades from additional firms.
Bulls vs Bears: LMND Investment Factors
Lemonade presents a compelling growth story with accelerating revenue (53.3% YoY) and improving margins, but its valuation remains stretched at a trailing PS of 6.93 versus the industry average of 1.5. The bull case rests on the company's AI-driven disruption, improving loss ratio, and path to profitability, supported by a solid balance sheet. The bear case highlights the expensive valuation, limited analyst coverage, and continued losses that leave no room for error. The single most important tension is whether Lemonade can achieve sustained profitability and justify its premium valuation, or if growth deceleration or adverse claims will trigger a re-rating. Currently, the evidence slightly favors the bulls given the accelerating growth and improving fundamentals, but the high valuation demands execution perfection.
Bullish
- Accelerating Revenue Growth: Revenue grew 53.3% YoY in Q4 2025 to $228.1M, marking the fourth consecutive quarter of accelerating growth from 22% in Q4 2024. This outpaces the insurance industry average of 5-10%, indicating strong market share gains.
- Improving Profitability Trajectory: Net loss narrowed from -$62.4M in Q1 2025 to -$21.7M in Q4 2025, with net margin improving from -41.3% to -9.5%. Free cash flow turned positive at $17.6M in Q4 2025, signaling a clear path to profitability.
- AI-First Disruption and Partnerships: Lemonade's AI-driven platform and data-sharing partnership with Tesla for autonomous vehicle insurance provide a first-mover advantage. This positions the company to capture emerging markets and differentiate from legacy insurers.
- Solid Balance Sheet with Low Debt: The company holds $396.8M in cash with a debt-to-equity ratio of 0.34, providing ample liquidity to fund growth. The current ratio of 1.52 indicates adequate short-term solvency.
Bearish
- Expensive Valuation Despite Losses: Trailing PS ratio of 6.93 is 362% above the industry average of 1.5, and the company remains unprofitable with negative EPS of -$0.33. The market is pricing in significant future growth that may not materialize.
- Limited Analyst Coverage and Volatility: Only 2 analysts cover LMND, leading to inefficient price discovery. The stock's beta of 1.785 makes it highly volatile, with a 52-week range of $35.70 to $99.90, exposing investors to sharp swings.
- Morgan Stanley Downgrade on Valuation: On July 8, 2026, Morgan Stanley downgraded LMND to Hold, citing valuation concerns after a 50% rally and a softening auto insurance market. This highlights the risk of a pullback after strong gains.
- Continued Net Losses and Negative ROE: Despite improvement, LMND still posted a net loss of -$21.7M in Q4 2025 and a ROE of -31.0%. The company has not yet achieved sustained profitability, making it vulnerable to adverse underwriting events.
LMND Technical Analysis
Lemonade's stock is in a strong recovery uptrend, with a 1-year price change of +77.3%, significantly outperforming the S&P 500's +20.6% gain. The current price of $70.51 sits at 55.6% of its 52-week range ($35.70 to $99.90), indicating room to run but still below the highs. This positioning suggests the stock has rebounded from its lows but is not yet overextended, offering a potential entry point for momentum investors. Short-term momentum is accelerating sharply, with a 1-month change of +26.2% and a 3-month change of +29.5%, both outpacing the S&P 500's 4.1% and 11.1% gains, respectively. The 1-month relative strength of 22.2% versus the market confirms strong recent buying pressure, diverging positively from the 6-month decline of -11.5%, which signals a potential trend reversal from the earlier downtrend. The stock's beta of 1.785 indicates it is 78.5% more volatile than the market, amplifying both upside and downside moves. Key support lies at the 52-week low of $35.70, while resistance is at the 52-week high of $99.90. A breakout above $99.90 would signal a resumption of the long-term uptrend, while a breakdown below $35.70 would indicate a bearish reversal. Given the high beta, position sizing should account for potential sharp swings.
Beta
1.78
1.78x market volatility
Max Drawdown
-47.7%
Largest decline past year
52-Week Range
$36-$100
Price range past year
Annual Return
+85.0%
Cumulative gain past year
| Period | LMND Return | S&P 500 |
|---|---|---|
| 1m | +22.8% | +1.0% |
| 3m | +13.0% | +7.9% |
| 6m | -13.0% | +8.5% |
| 1y | +85.0% | +20.1% |
| ytd | -7.0% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LMND Fundamental Analysis
Lemonade's revenue trajectory is accelerating strongly, with Q4 2025 revenue of $228.1 million representing 53.3% year-over-year growth, up from 22.0% growth in Q4 2024. This marks the fourth consecutive quarter of accelerating growth, from $119.1 million in Q1 2024 to $228.1 million in Q4 2025, driven by customer acquisition and premium expansion. The company operates as a single reportable segment, with no further revenue breakdown provided. The accelerating growth supports the bull case that Lemonade is gaining market share and scaling its AI-driven model effectively. The company remains unprofitable, with a net loss of -$21.7 million in Q4 2025, though this loss narrowed significantly from -$62.4 million in Q1 2025. Gross margin improved to 63.0% in Q4 2025 from 26.3% in Q1 2025, reflecting better underwriting and cost management. The net margin improved to -9.5% from -41.3% over the same period, indicating a clear trajectory toward profitability, though the company still posted negative EPS of -$0.33. Lemonade's balance sheet is solid, with $396.8 million in cash at the end of Q4 2025 and a debt-to-equity ratio of 0.34, indicating low leverage. Free cash flow turned positive at $17.6 million in Q4 2025, compared to -$49.5 million in Q1 2025, demonstrating improving cash generation. The current ratio of 1.52 suggests adequate liquidity, and the ROE of -31.0% reflects ongoing losses, but the trend is improving.
Quarterly Revenue
$228100000.0B
2025-12
Revenue YoY Growth
+53.3%
YoY Comparison
Gross Margin
62.9%
Latest Quarter
Free Cash Flow
$-25900000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LMND Overvalued?
Since Lemonade has negative net income (EPS of -$0.33), the price-to-sales (PS) ratio is the most appropriate valuation metric. The trailing PS ratio is 6.93, while the forward PS ratio is not directly provided but can be estimated using the average revenue estimate of $2.607 billion for the next fiscal year, implying a forward PS of approximately 1.96 (market cap of $5.112 billion / $2.607 billion). The large gap between trailing and forward PS reflects the market's expectation of rapid revenue growth. Compared to the property and casualty insurance industry average PS ratio of approximately 1.5 (based on industry data), Lemonade's trailing PS of 6.93 represents a 362% premium, while its forward PS of 1.96 is a 31% premium. The premium is justified by Lemonade's superior revenue growth (53% YoY) versus the industry average of around 5-10%, but the valuation remains stretched for a company that is not yet profitable. Historically, Lemonade's PS ratio has ranged from a low of around 7.1 in Q3 2023 to a high of 238.6 in Q1 2021. The current trailing PS of 6.93 is near the lower end of its historical range, suggesting that the stock is not overvalued relative to its own history. However, the forward PS of 1.96 is near the bottom of the historical band, indicating that the market is pricing in significant growth but not the extreme optimism seen in 2021.
PE
-30.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -59x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-33.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Lemonade's primary financial risk is its continued unprofitability, with a net loss of -$21.7M in Q4 2025 and negative EPS of -$0.33. Although the loss is narrowing, the company has not demonstrated consistent profitability, and any adverse claims experience could reverse progress. The negative free cash flow of -$25.9M TTM (though positive in Q4) indicates cash burn, though the $396.8M cash cushion provides a buffer. Revenue concentration in a single segment (P&C insurance) exposes the company to underwriting cycles and catastrophic events. Market & Competitive Risks: The stock's beta of 1.785 makes it highly sensitive to market sentiment, and its trailing PS of 6.93 is a 362% premium to the industry average, creating valuation compression risk if growth slows. The Morgan Stanley downgrade on July 8, 2026, highlights that the stock's 50% rally may have outpaced fundamentals. Competition from legacy insurers with larger balance sheets and AI investments could erode Lemonade's first-mover advantage. Regulatory changes in insurance markets or data privacy laws could also impact operations. Worst-Case Scenario: A combination of slowing revenue growth (e.g., below 30%), a spike in claims from a catastrophic event, and a broad market sell-off could drive the stock back toward its 52-week low of $35.70. From the current price of $70.51, this represents a potential loss of -49.4%. The analyst bear-case target is not explicitly provided, but the 52-week low implies a realistic downside of approximately -49% in an adverse scenario where the company fails to achieve profitability and growth decelerates.
FAQ
The primary risks are: 1) Valuation risk: The trailing PS of 6.93 leaves little room for error, and any growth deceleration could trigger a sharp re-rating. 2) Profitability risk: Despite improvement, the company still posted a net loss of -$21.7M in Q4 2025, and a catastrophic claims event could reverse progress. 3) Competitive risk: Legacy insurers are investing in AI, and Lemonade's first-mover advantage may erode. 4) Macro risk: With a beta of 1.785, the stock is highly sensitive to market downturns and rising interest rates. The most severe risk is a growth slowdown combined with a market sell-off, which could drive the stock down 49% to its 52-week low of $35.70.
The 12-month outlook is balanced with a base case probability of 50% for a price range of $65-$80, assuming revenue growth moderates to 35-40% and margins continue to improve. The bull case (25% probability) targets $90-$100, driven by sustained 50%+ growth and positive net income. The bear case (25% probability) sees the stock falling to $40-$55 if growth decelerates below 20% or claims spike. The most likely scenario is the base case, where the stock trades in a range as investors await profitability. Key catalysts include the next earnings report and developments in the Tesla partnership.
Lemonade's trailing PS of 6.93 is significantly overvalued compared to the property and casualty insurance industry average of 1.5, representing a 362% premium. However, the forward PS of 1.96 (based on estimated revenue of $2.607B) is much closer to the industry average, reflecting the market's expectation of rapid growth. Historically, the stock's PS has ranged from 7.1 to 238.6, so the current level is near the lower end of its own history. The valuation implies that the market expects continued high growth and eventual profitability. Given the company's losses, traditional PE-based valuation is not applicable. Overall, LMND is overvalued on a trailing basis but fairly valued on forward metrics if growth materializes.
Lemonade is a high-risk, high-reward stock that may be suitable for aggressive growth investors with a long-term horizon. The company's revenue growth of 53.3% YoY and improving margins are compelling, but the trailing PS of 6.93 is 362% above the industry average, implying high expectations. With only 2 analysts covering the stock, there is limited consensus on fair value. The stock is a good buy for those who believe in the AI-driven insurance disruption and can tolerate volatility (beta 1.785), but it is not appropriate for risk-averse investors. A disciplined entry near support levels (e.g., $50-$55) would improve the risk/reward profile.
Lemonade is better suited for long-term investment (3-5 years) given its high growth and early stage of profitability. The stock's beta of 1.785 makes it too volatile for short-term trading, with sharp swings that can trigger stop-losses. The company does not pay a dividend, so returns depend entirely on capital appreciation. Long-term investors can benefit from the compounding effect of revenue growth and margin expansion as the company scales. A minimum holding period of 3 years is recommended to allow the AI-driven model to prove its profitability. Short-term traders may find opportunities around earnings, but the risk of gap moves is high.